Company Overview and News

Accor Form EX-99.D

Exhibit 99.D   Joint Filing Agreement   Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of ordinary shares and American depositary shares of China Lodging Group, Limited.   EXECUTED this 5th day of February, 2016.

Accor Form EX-99.B

Exhibit 99.B   EXECUTION VERSION   AMENDED AND RESTATED NON-COMPETITION AGREEMENT   DATED 14 DECEMBER, 2014 AND AMENDED AND RESTATED ON January 25, 2016   Between   ACCOR S.A.   and   AAPC HONG KONG LIMITED   and   CHINA LODGING GROUP, LIMITED   and   QI JI     This agreement was made the 14th day of December 2014 and is amended and restated on 25th day of January 2016 (“Agreement”)   BETWEEN:   (1)                                 Accor S.

Accor Form SC 13D (Acquisition of More Than 5% of Shares)

    UNITED STATES     SECURITIES AND EXCHANGE COMMISSION     Washington, D.C. 20549           SCHEDULE 13D     Under the Securities Exchange Act of 1934 (Amendment No.     )*   China Lodging Group, Limited (Name of Issuer)   Ordinary Shares, $.0001 par value; ADSs, representing 4 ordinary shares per ADS (Title of Class of Securities)   G2118 103; 16949N109 (CUSIP Number)   François Pinon Group General Counsel 110 Avenue de France, 75210 Paris, France +33 (0) 1 45 38 87 33   Copies to: Michael Is

Market Influences That Drive Equities Forward - Comprehensive Research on South32, Accor, Localiza Rent a Car, and FRMO Corp.

2016-01-25 accesswire
NEW YORK, NY / ACCESSWIRE / January 25, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: South32 Ltd. (OTC: SOUHY), Accor SA (OTC: ACCYY), Localiza Rent a Car SA (OTC: LZRFY) and FRMO Corp. (OTC: FRMO). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year.

How it All Plays Out - Complementary Research on Accor, BYD Co, Astra International, and Finmeccanica

2016-01-20 accesswire
NEW YORK, NY / ACCESSWIRE / January 20, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Accor SA (OTC: ACCYY), BYD Co Ltd. (OTC: BYDDY), Astra International Tbk PT (OTC: PTAIY), Finmeccanica SpA (OTC: FINMY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year.

Goldman Sachs invests US$ 66 million in Samhi Hotels

2016-01-17 financialexpress
Global investment firm Goldman Sachs has invested US$66 million for a minority stake in Indian hotel investment and development firm Samhi Hotels, the companies said in a statement

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...